Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00566098 · OUTCOME

Survival

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma · Source last updated 2023-05-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Up to 129 months

What was measured

Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a \>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.

Groups in this outcome

MILs in Patients Undergoing an Autologous Peripheral SCT

therapeutic autologous lymphocytes

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MILs in Patients Undergoing an Autologous Peripheral SCT22

Reported measurements

Overall survival
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
MILs in Patients Undergoing an Autologous Peripheral SCT112.1Not reported39.9128.7Not reported
Progression-free survival
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
MILs in Patients Undergoing an Autologous Peripheral SCT12.3Not reported8.869.03Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        39.9
        upper Limit
        128.7
        value
        112.1
    title
    Overall survival
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        8.8
        upper Limit
        69.03
        value
        12.3
    title
    Progression-free survival
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
description
Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a \>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.
dispersion Type
Full Range
groups
  1. description
    therapeutic autologous lymphocytes
    id
    OG000
    title
    MILs in Patients Undergoing an Autologous Peripheral SCT
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 129 months
title
Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice